Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes

What Was Tested

This randomized controlled trial paper looks at Insulin Aspart and NPH Insulin (isophane).

Who Took Part

The abstract describes 30 people taking part.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, open-label and parallel-group study.

Because people in this Insulin Aspart study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label Insulin Aspart study: the people and staff both knew the treatment.

Groups ran in parallel: each of the people stayed in one arm throughout.

What Was Measured

PubMed files the paper under topics including Biphasic Insulins, Blood Glucose, Blood Glucose Self-Monitoring, Diabetes Mellitus, Type 2, Drug Combinations, Drug Monitoring and Glycated Hemoglobin.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Insulin Aspart and NPH Insulin (isophane) in 30 people.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2016 (Diabetic medicine : a journal of the British Diabetic Association), a journal based in England.

More context: the Insulin Aspart compound page and the NPH Insulin (isophane) compound page.